ATNMHIGH SIGNALFINANCIAL10-K

Actinium Pharmaceuticals shows severe stockholders equity deterioration declining 76% while burning through substantial cash reserves.

The dramatic equity decline combined with meaningful cash burn raises immediate concerns about the company's financial stability and ability to fund ongoing operations. Despite modest improvements in operating losses and cash flow efficiency, the overall financial position has weakened substantially, which could impact the company's ability to advance its clinical pipeline without additional financing.

Comparing 2026-03-30 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

ATNM's financial position deteriorated significantly with stockholders equity collapsing 76% to just $7.8M while cash reserves declined 34% to $48.0M. The company did show some operational improvement with R&D expenses reduced 30% and operating losses narrowing modestly, along with more efficient cash utilization. However, the severe equity erosion overshadows these operational gains and signals potential going-concern issues for this clinical-stage biopharmaceutical company.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-76.1%
$32.8M$7.8M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Interest Expense
P&L
-36.4%
$8K$5K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Cash & Equivalents
Balance Sheet
-34.2%
$72.9M$48.0M

Cash declined 34.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-33.7%
$74.5M$49.4M

Current assets declined 33.7% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-32.7%
$76.9M$51.8M

Total assets contracted 32.7% — asset sales, write-downs, or balance sheet optimization underway.

R&D Expense
P&L
-29.7%
$30.0M$21.1M

R&D spending cut 29.7% — could signal cost discipline or concerning reduction in innovation investment.

Operating Cash Flow
Cash Flow
+25.7%
-$33.1M-$24.6M

Operating cash flow grew 25.7% — strong conversion of earnings to cash, healthy business fundamentals.

Operating Income
P&L
+13.9%
-$42.1M-$36.2M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+11.4%
-$38.2M-$33.9M

Net income grew 11.4% — bottom-line growth signals improving overall business health.

Revenue
P&L
+11.1%
$81K$90K

Revenue growing 11.1% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-31
ADDED
As of March 30, 2026, 31,374,994 shares of common stock, $0.001 par value per share, were outstanding.
Description of Our Business We are a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology.
We are focused on employing a biology-driven approach to develop differentiated, first-in-class radiopharmaceutical therapeutics for patients with solid tumors and hematologic malignancies.
Our mission is to transform cancer treatment by delivering innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining our deep understanding of tumor biology and translational medicine with our expertise in radiochemistry.
Since our inception, we have focused on developing innovative and differentiated radiotherapies.
+7 more — sign up free →
REMOVED
As of March 28, 2025, 31,195,891 shares of common stock, $0.001 par value per share, were outstanding.
( Actinium , the Company , or we ) is a pioneer in the development of targeted radiotherapies intended to meaningfully improve outcomes for patients with advanced cancers including relapsed or refractory ( r/r ) disease who have failed existing therapies.
We are advancing a pipeline of differentiated clinical stage product candidates focused on validated cancer targets.
Our current pipeline is focused on indications in myeloid malignancies, solid tumors and conditioning for cell and gene therapies that we believe have high unmet needs that are not addressed by currently available treatment options.
Our goal is to create a specialty radiopharmaceutical company with capabilities across radioisotope production, final drug product manufacturing, preclinical research and development ( R D ) and clinical development.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →